🇺🇸 FDA
Pipeline program

Toripalimab

SYSUCC-025

Phase 2 small_molecule active

Quick answer

Toripalimab for Triple-Negative Breast Cancer (TNBC) is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Triple-Negative Breast Cancer (TNBC)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials